Activation of vitamin D in the gingival epithelium and its role in gingival inflammation and alveolar bone loss

Lorenzo P. Menzel¹ | Willam Ruddick¹ | Mobaswar H. Chowdhury¹ | David C. Brice¹ | Ryan Clance¹ | Emily Porcelli¹ | Lisa K. Ryan² | Jungnam Lee³ | Özlem Yilmaz⁴,⁵ | Keith L. Kirkwood⁶ | Laura McMahon⁷ | Amy Tran⁷ | Gill Diamond¹

¹Department of Oral Biology, University of Florida, Gainesville, Florida
²Division of Infectious Diseases and Global Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida
³Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, Florida
⁴Department of Oral Biology, State University of New York at Buffalo, Buffalo, New York
⁵Department of Oral Biology, Rutgers New Jersey Dental School, Newark, New Jersey

Background and Objective: Both chronic and aggressive periodontal disease are associated with vitamin D deficiency. The active form of vitamin D, 1,25(OH)₂D₃, induces the expression of the antimicrobial peptide LL-37 and innate immune mediators in cultured human gingival epithelial cells (GECs). The aim of this study was to further delineate the mechanism by which vitamin D enhances the innate defense against the development of periodontal disease (PD).

Materials and Methods: Wild-type C57Bl/6 mice were made deficient in vitamin D by dietary restriction. Cultured primary and immortalized GEC were stimulated with 1,25(OH)₂D₃, followed by infection with Porphyromonas gingivalis, and viable intracellular bacteria were quantified. Conversion of vitamin D₃ to 25(OH)D₃ and 1,25(OH)₂D₃ was quantified by ELISA. Effect of vitamin D on basal IL-1α expression in mice was determined by topical administration to the gingiva of wild-type mice, followed by qRT-PCR.

Results: Dietary restriction of vitamin D led to alveolar bone loss and increased inflammation in the gingiva in the mouse model. In primary human GEC and established human cell lines, treatment of GEC with 1,25(OH)₂D₃ inhibited the intracellular growth of P. gingivalis. Cultured GEC expressed two 25-hydroxyases (CYP27A1 and CYP2R1), as well as 1-α-hydroxylase, enabling conversion of vitamin D to both 25(OH)D₃ and 1,25(OH)₂D₃. Topical application of both vitamin D₃ and 1,25(OH)₂D₃ to the gingiva of mice led to rapid inhibition of IL-1α expression, a prominent pro-inflammatory cytokine associated with inflammation, which also exhibited more than a 2-fold decrease from basal levels in OKF6/TERT1 cells upon 1,25(OH)₂D₃ treatment, as determined by RNA-seq.

Conclusion: Vitamin D deficiency in mice contributes to PD, recapitulating the association seen in humans, and provides a unique model to study the development of PD. Vitamin D increases the activity of GEC against the invasion of periodontal pathogens and inhibits the inflammatory response, both in vitro and in vivo. GEC can convert inactive vitamin D to the active form in situ, supporting the hypothesis that vitamin D can be applied directly to the gingiva to prevent or treat periodontal disease.

Keywords:
antimicrobial peptide, inflammation, periodontal disease, vitamin D
1 | INTRODUCTION

Periodontal disease is an inflammatory disease of the gums and supporting tissues that, if untreated, can lead to tooth loss, and may also affect systemic health. It is associated with a dysbiosis of the commensal microbiota in the subgingival crevice, leading to an increase in specific pathogenic bacteria, including Porphyromonas gingivalis, and a subsequent inflammatory response. This inflammation then leads to bone resorption, and ultimately tooth loss (reviewed in 1).

Vitamin D is best known as a principal factor that maintains calcium homeostasis and is required for bone development and maintenance. However, it is becoming clear that vitamin D has profound effects on immunity and inflammation as well (reviewed in 2). The active form of vitamin D, 1,25(OH)D3, can induce the expression of antimicrobial peptides and other innate immune mediators in a variety of cell types (reviewed in 3). Furthermore, 1,25(OH)2D3 exhibits anti-inflammatory activity through the inhibition of pro-inflammatory cytokine gene expression.4 Experimental deficiency in a mouse model leads to an increase in bacterial infection in the bladder.5

Periodontal disease has been associated with vitamin D deficiency in numerous populations6-9 although the mechanism by which this occurs is not known. This may be due to the effect of vitamin D on both the innate immune activity of the gingival epithelium against periodontal pathogens to maintain microbial homeostasis10 and the inhibition of pro-inflammatory cytokines. We have shown 1,25(OH)2D3, induces the expression of the antimicrobial peptide LL-37 in cultured gingival epithelial cells (GECs), and that this treatment leads to a reduction in the viability of the periodontal pathogen Aggregatibacter actinomycetemcomitans on the surface of the cells.11 It was recently demonstrated that injection of 25-hydroxyvitamin D3, or 25(OH)D3, into mice prevented the bone loss in a diabetic periodontitis model with infection of P. gingivalis, through the inhibition of the JAK/STAT3 pathway.12 Deletion of the CYP27B1 gene in mice, which encodes the enzyme responsible for the final activation step of vitamin D, leads to accelerated bone loss and an increase in pro-inflammatory cytokines.13 Together, this suggests that physiologically sufficient levels of vitamin D, maintained by oral supplementation, can support overall periodontal health.

Indeed, the vast majority of research into the activity and effects of vitamin D in human health has focused on systemic introduction, usually by oral supplementation, as vitamin D is very safe, even at high doses, and easily absorbed and stored.14 This has led to mixed results, most likely because oral supplementation can only increase serum 25(OH)D3 levels (and tissue levels of 1,25(OH)2D3) to a limited degree. Similarly, Gui et al15 showed that while systemic administration of 1,25(OH)2D3 (by daily intraperitoneal injection over 2 weeks) initially led to reduced inflammation, there were negative effects in the long term. Therefore, we wished to examine the potential for topical administration of vitamin D to the oral cavity. However, the active, 1,25(OH)2D3, form is very labile, and not very suitable for direct application. This form is produced by two sequential hydroxylations of vitamin D. It has been generally accepted that this occurs initially by one of a number of 25-hydroxylases in the liver (leading to 25(OH)D2), and then by 25-hydroxyvitamin D1α-hydroxylase (1α- (OH)ase) in the kidney.16 Recently, however, other cell types, including epithelial, breast, prostate, and immune system cells (monocytes, macrophages, and dendritic cells), have been shown to produce the vitamin D-activating 1α-hydroxylase.17,18 Therefore, we hypothesized that gingival epithelial cells can activate inactive vitamin D and allow the topical application of vitamin D to the oral cavity to induce an innate immune response. Here, we examine the potential of a novel local mechanism of vitamin D activation in GEC, demonstrate a mouse model of periodontal disease due to vitamin D insufficiency, and examine the feasibility of delivering inactive vitamin D to the oral cavity to regulate innate immune gene expression to maintain periodontal health.

2 | MATERIAL AND METHODS

2.1 | Bacteria

Porphyromonas gingivalis ATCC 33277 was maintained as frozen stock cultures and grown anaerobically at 37°C in trypticase soy broth supplemented with 1 g of yeast extract per liter, 5 mg of hemin per liter, and 1 mg of menadione per liter.

2.2 | Cell cultures

The human oral keratinocyte cell line OKF6/TERT1 was grown as frozen stock cultures and grown anaerobically at 37°C in trypticase soy broth supplemented with L-glutamine and penicillin-streptomycin-fungizone (Sigma-Aldrich) in the presence of 0.03 mol/L calcium chloride and bovine pituitary extract as described previously.11 Primary cultures of normal human gingival epithelial cells were grown as previously described.19,20

2.3 | Vitamin D

Vitamin D3, 25(OH)D3 and 1,25(OH)2D3 (Sigma) were dissolved in 100% ethanol at 10⁻⁵ mol/L and kept in the dark at −20°C. Stocks were diluted to 10⁻⁸ mol/L fresh prior to each use in sterile medium or PBS. Control vehicle was 0.1% ethanol in sterile medium or PBS. We observed no toxic effect of either the vitamin D metabolites at this concentration, nor of the vehicle control (data not shown).

2.4 | Intracellular P. gingivalis assays

Porphyromonas gingivalis ATCC 33277 was cultured anaerobically at 37°C for 24 hours in trypticase soy broth supplemented with yeast extract (1 mg/mL), haemin (5 μg/mL), and menadione (1 μg/mL) and harvested by centrifugation at 600 g and 4°C for 10 minutes. The bacterial pellet was resuspended in Dulbecco’s phosphate-buffered saline (Sigma) pH 7.3, and the number of bacteria was determined using a Klett-Summerson photometer.
Primary GECs were obtained after oral surgery from healthy gingival tissue as previously described\textsuperscript{21,22}. Cells were cultured as monolayers in serum-free keratinocyte growth medium (KGM) (Lonza) at 37°C in 5% CO\textsubscript{2}. When GECs were at ~75%-80% confluence, they were treated with 1,25(OH)\textsubscript{2}D\textsubscript{3} or vehicle control (0.1% ethanol) for three hours. The medium was removed, and the 1α,25(OH)\textsubscript{2}D\textsubscript{3}-treated cells were co-incubated with \textit{P. gingivalis} at a multiplicity of infection of 100 (MOI = 100) for 24 hours. After the incubation, cells were fixed with 4% paraformaldehyde, permeabilized by 0.1% Triton X-100, and stained for one hour at room temperature with a rabbit polyclonal antibody against \textit{P. gingivalis} ATCC 33277 (1:500). The stained cells were washed with PBS containing Tween-20 and incubated for one hour at room temperature with Alexa Fluor 568-conjugated secondary goat anti-rabbit polyclonal antibody (1:1000; Invitrogen). Cellular boundaries were determined from the actin cytoskeleton staining (phalloidin-TRITC, staining red). Mean fluorescence, cell area, and the integrated density for each cell were measured by the software. The corrected total cell fluorescence (CTCF) was calculated as follows: CTCF = Integrated density − (Area of selected cell × Mean fluorescence of background readings).\textsuperscript{24} A minimum of 20 cells, originating from at least three separate experiments, were evaluated for each experimental condition.\textsuperscript{25} A 40X objective was used to obtain the images.

The effect of vitamin D on immortalized gingival cells was determined by treating cultures of OKF6/TERT1 cells for 24 hours with 10 nm 1,25(OH)\textsubscript{2}D\textsubscript{3} or 0.1% ethanol. Cultures were washed 4x with PBS and were co-incubated with \textit{P. gingivalis} (MOI = 100) for 90 minutes. Cells were then washed 4x again in PBS and treated with metronidazole/gentamicin in media for another 60-minute incubation to kill externally adherent \textit{P. gingivalis}. Cells were washed 4x more in PBS, scraped on ice with ice-cold PBS, and lysed by freeze-thaw at -80°C. Serial dilutions of lysates were plated to quantify viable colonies of \textit{P. gingivalis}.

### 2.5 Quantification of mRNA

Total nucleic acids were extracted from tissue culture GECs or homogenized gingival tissue with QiShredder spin columns and the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s guidelines. Bio-Rad’s iScript cDNA library kit (1708891) was used according to the supplied directions. Relative mRNA levels were measured with a SsoAdvanced Universal SYBR Green Supermix (Bio-Rad 1725274) on a Bio-Rad CFX96 Touch Real-Time PCR Detection System thermal cycler (1855195) in 96-well plates (Bio-Rad HASP9601), and quantified according to the \textsuperscript{2}\textsuperscript{ΔΔCq} method, relative to β-actin as a housekeeping gene, and control-treated cultures or tissue.

### 2.6 Mice

C57Bl/6 mice (Charles River), 8 weeks old, were housed in a barrier facility at the University of Florida. All experimental protocols were approved by the University of Florida Institutional Animal Care and Use Committee (IACUC) (protocol number 07970). All methods were carried out in accordance with relevant guidelines and regulations. Animals were housed in groups of five. Each study group incorporated five mice.

### 2.7 Vitamin D diets

After acclimating the mice to their new environment for 2 weeks, their diets were replaced with custom-mixed, irradiated diets purchased from Harlan Teklad. To induce vitamin D deficiency, we utilized a diet free of vitamin D\textsubscript{3}, containing 0.02% calcium (Harlan Teklad 00562). The control diet (Harlan Teklad 140510) contained standard levels of vitamin D3 and calcium (1000 IU and 0.8%, respectively). All animals were maintained on their respective diets and vitamin D levels for 6 weeks. At the end of the 6 weeks, mice were humanely sacrificed by CO\textsubscript{2}, and gingivae were excised with a scalpel, and placed in RNAlater prior to RNA extraction (Qiagen). Blood was sampled for quantification of serum 25OHD\textsubscript{3} (see below). Subsequently, skulls and mandibles were removed for analysis.

### 2.8 Serum vitamin D levels

Whole blood was collected by cardiac exsanguination, allowed to clot for 30 minutes at room temperature before centrifugation, and the resulting serum was stored at -80°C before being shipped to Heartland Assays, Inc. for the analysis of vitamin D\textsubscript{3}, 25(OH)D\textsubscript{3}, and 1,25(OH)\textsubscript{2}D\textsubscript{3} levels by radioimmunoassay.

### 2.9 Alveolar bone analysis

Harvested murine heads were fixed in formalin for 72 hours, washed with PBS, and stored in 70% ethanol for μCT analysis. Maxillae were scanned at 55 kVp, 145 μA, 16 μm voxel resolution using Scanco Medical 40 μCT scanner (Scanco Medical, Brüttschellen, Switzerland). Three-dimensional images were generated and reconstructed for each specimen. These images were rotated with a standard orientation and threshold to discern mineralized and non-mineralized tissue. The region of interest (ROI) was indicated by the contour height of molars (M1-M3) at the cementoenamel junction as the width and the molar cusp tips to root apices as the height as recently reported.\textsuperscript{26} Depth was equal to the buccolingual size of the teeth plus 1.0 mm\textsuperscript{3}. Bone volume fraction was calculated as the percentage of bone within the ROI using AnalyzePro software (Seattle, WA). Data are reported in accordance with standardized nomenclature.\textsuperscript{27}
2.10 | Histomorphometry

Following μCT, maxillae were decalcified as previously described. Specimens were paraffin-embedded, and serial sagittal sections were cut through the distal maxillae for alveolar bone analyses. 7-μm sections were stained with hematoxylin and eosin (H&E) to assess tissue inflammation. Inflammation was scored in the maxillary periodontal tissues between M1 and M2 using the following scoring system: 0 = 0%-5% inflammatory cell (IC) infiltration, 1 = 5%-25% ICs, 2 = 25%-50% ICs, and 3 = >50% ICs as recently reported. 7-μm sections were stained with tartrate-resistant acid phosphate (TRAP) and aniline blue (counterstain) to quantify osteoclast cellular endpoints in the interradicular area as recently reported. TRAP-positive area (red-color staining) and eroded bone perimeters were quantified using Visiopharm software (Hoersholm, Denmark). Data are reported in accordance with standardized nomenclature.

2.11 | In vivo administration of vitamin D

Gingivae of mice were treated by topically applying 50 μL 1 μmol/L 1,25(OH)₂D₃ in mineral oil or vehicle control. After 6 hours, mice were sacrificed, and gingivae were excised and placed in RNAlater. Total mRNA was isolated using RNeasy Plus (Qiagen), and relative IL-1α mRNA levels were quantified by qPCR as above.

2.12 | RNA-seq

Triplicate cultures of OKF6/TERT1 cells were treated with 10 nmol/L 1,25(OH)₂D₃ in 0.1% ethanol or vehicle control for 24 hours. Total mRNA was isolated using RNeasy Plus Mini Kit (Qiagen, 74136). cDNA was then prepared using TruSeq Library Prep Kit (Illumina) according to the manufacturer’s protocol and was sequenced on the NextSeq 500 sequencer (Illumina). Sequences were analyzed via Patterned Alignments for Splicing and Transcriptome Analysis (PASTA) software. Relative expression between sample treatments was calculated for each transcript. Transcripts with greater than a 2-fold log₂ change that was statistically significant (adj-P < 0.05 for two-tailed unpaired Student’s t test) were then further analyzed. The resulting list of over 23 000 genes was trimmed to those which were significantly (adjusted P-value <0.05), and substantially (absolute value log₂ fold change >2) changed in expression (3173 genes). The list was then cross-referenced with the innate immunity gene database (innate-db.com) to identify innate immune genes regulated by vitamin D.

2.13 | Quantification of vitamin D metabolites

OKF6/TERT1 cells (n = 3) were treated with either 10 nmol/L vitamin D₃ or 25(OH)D₃ in 0.1% ethanol vehicle, which was used as a negative control. Supernatants were collected, and 25OHD₃ and 1,25(OH)₂D₃ were measured by enzyme immunoassay (EIA) (Eagle Biosciences) according to the manufacturer’s instructions. Media with vitamin D₃ or 25(OH)D₃ alone was also assessed for cross-reactivity, and these values were subtracted from the total levels reported.

2.14 | Statistical analysis

Power calculations (α = 0.05; power = 80%) to determine group size in the mouse experiments were carried out using means and standard deviations from preliminary experiments, to provide a significant difference between the groups. Differences between treated and untreated groups were analyzed by two-tailed, unpaired t test with commercially available software. Significance was set at P < 0.05.

3 | RESULTS

3.1 | Effect of vitamin D deficiency on gingival inflammation and alveolar bone loss

While epidemiological associations between serum vitamin D levels and periodontal disease in humans have been observed, we wished to recapitulate this in a mouse model for further studies. Wild-type (C57Bl/6) mice were fed either a normal diet, including vitamin D, or a diet absent vitamin D for 6 weeks. Serum samples from the mice at the end of 6 weeks showed that the mice fed a vitamin D-absent diet exhibited very low levels of 25(OH)D₃ (Figure 1A). While this diet includes reduced calcium as well, this has been shown to lead to no reduction in serum calcium levels, even up to 8 weeks. Longer depletion of vitamin D would compromise the general health of the mice, potentially confounding the model. To determine whether this vitamin D deficiency can lead to symptoms associated with periodontal disease, we quantified the alveolar bone in mice fed the vitamin D-deficient diet compared with the vitamin D-replete diet. The results show a clear reduction in alveolar bone in the vitamin D-deficient group compared with the control as measured by micro-CT analysis of bone volume (Figure 1B) and an increase in osteoclasts, as measured by TRAP staining (Figure 1C). In addition, there was a significant amount of inflammation in the gingival epithelium of the vitamin D-deficient group (Figure 1D).

3.2 | Effect of vitamin D on intracellular P. gingivalis in GEC

We examined the effect of vitamin D treatment of GEC on the presence of intracellular P. gingivalis in cultured GEC. Primary cultures of GEC are pre-treated with 10 nmol/L 1,25(OH)₂D₃ for 24 hours, this leads to a concomitant decrease in intracellular P. gingivalis as observed by fluorescence microscopy (Figure 2A, and quantified in Figure 2B). A similar reduction of observed intracellular P. gingivalis in cultured OKF6/TERT1 cells is seen without pre-treatment, when the 1,25(OH)₂D₃ is added at the same time as the P. gingivalis (2C). Together, the results indicate that the active form of vitamin D can elicit an innate immune defense against periodontal pathogens in GEC.
3.3 | Conversion of inactive vitamin D to the active form by cultured GEC

To determine whether cultured GEC can respond to the inactive vitamin D form, we treated OKF6/TERT1 cells with 10 nmol/L vitamin D3, 25OHD3 or 1,25(OH)2D3, for 24 and 48 hours. The results in Figure 3A show an induction of LL-37 mRNA levels in response to all three metabolites, suggesting that in addition to being able to respond to the active form, these cells can convert vitamin D to 25(OH)D3, and from there to 1,25(OH)2D3. To confirm this, and to identify the mechanism, we performed RT-PCR to determine the expression of vitamin D hydroxylases. Visible bands in gel electrophoresis of the RT-PCR products (not shown) demonstrated the expression of two 25-hydroxylases (CYP2R1 and CYP27A1), and the sole 1-α-hydroxylase, CYP27B1. Expression of these genes was not regulated by 1,25(OH)2D3 as measured by qRT-PCR, as shown in Figure 3B. To confirm the activity of these enzymes, we added 10 μM vitamin D or 25(OH)D3 to the cultures and quantified the activation products over time. The results in Figure 3C show that 25(OH)D3 is converted to 1,25(OH)2D3 over 24 hours, with a significant increase above background observed by 6 hours. Figure 3D similarly shows the conversion of vitamin D to 25(OH)D3 within 2 hours, although at a much lower level. No significant 25(OH)D3 was observed at longer incubations (data not shown). Thus, inactive vitamin D can be applied to GEC, which is rapidly converted to 25(OH)D3, and from there to 1,25(OH)2D3, which activates a transcriptional response.

3.4 | Effect of topical vitamin D treatment on inflammatory gene expression in vitro and in vivo

To examine the effect of vitamin D treatment on the inflammatory response in vivo, we first identified an appropriate, unstimulated pro-inflammatory cytokine. RNA-seq analysis of OKF6/TERT1 cells treated with 1,25(OH)2D3 yielded 25 transcripts that were associated with innate immunity or inflammation (Table S1). Based on our results, we chose to quantify the expression of the pro-inflammatory cytokine, IL-1α, since it plays an important role in periodontal inflammation and bone loss.33 When oral keratinocytes were treated with 10 nmol/L 1,25(OH)2D3, we observed an inhibition of basal IL-1α mRNA levels (Figure 4A).

We then examined the effect of topical administration of vitamin D in vivo, using mice fed a normal, vitamin D-replete diet. The results in Figure 4B show that topical vitamin D administration of both inactive vitamin D3 and 1,25(OH)2D3 leads to a rapid reduction in levels of IL-1α mRNA in the vitamin D-treated gingivae, compared with vehicle control.
Vitamin D has long been known to regulate calcium absorption in the body, which can subsequently affect numerous systems, especially bone resorption. As early as 1968, calcium deficiency was observed to lead to alveolar bone loss in a dog model and was also observed in a rat model. Furthermore, supplementation with both calcium and vitamin D has positive effects on periodontal health. Several studies have shown a correlation between low vitamin D levels and periodontal disease; however, the mechanism is not understood. Our results show that this association between low serum vitamin D levels and periodontal health can be recapitulated in a wild-type mouse model, thus allowing future studies into the specific mechanism that underlies this association. Our results further demonstrate that vitamin D insufficiency leads to increased gingival inflammation in the mouse under specific pathogen-free conditions. As a result of the inflammatory response, alveolar bone loss occurs. It is long understood that vitamin D maintains bone health, due to its role in the maintenance of calcium homeostasis. Furthermore, in order to maintain a complete deficiency of vitamin D, we used a diet low in calcium, which has been shown not to affect serum calcium levels. While mice with experimental periodontitis that were injected with 25(OH)D₃ showed decreased bone loss, as do CYP27B1−/− mice, our experiments are the first to demonstrate that a dietary deficiency in vitamin D leads to inflammation and alveolar bone loss.

In addition, we have devised a novel mouse model for the development of periodontal disease which does not rely on either mechanical stimulation (i.e., ligatures) or upon the introduction of human pathogens such as P. gingivalis. Furthermore, this model allows for the longitudinal analysis of components of the oral cavity during the development of periodontal disease, as well as the repeated delivery of potential anti-inflammatory drugs, and could thus be useful in preclinical testing of new therapies.

In susceptible hosts, colonization by pathobionts such as P. gingivalis into the oral cavity can ultimately lead to inflammation of the
gingival tissues, and bone loss that are the hallmarks of periodontal disease. Based on our earlier results showing that vitamin D stimulated the expression of antimicrobial peptide gene expression and activity in GEC, we hypothesized that physiologically sufficient levels of vitamin D could lead to an increased antimicrobial activity against keystone pathogens, and thus affect overall oral health. Our results showing the reduction in intracellular *P. gingivalis* in both cultured immortalized GEC and primary GEC support this hypothesis. While early in vitro studies suggested that LL-37, which is induced by vitamin D, exhibits low antimicrobial activity against *P. gingivalis* and other pathogens associated with periodontal disease, more recent studies have suggested that conditions found in vivo, both extracellular and intracellular, are more conducive to the antibacterial activity of LL-37 against these species.

While oral supplementation of vitamin D can lead to vitamin D sufficiency in vitamin D-deficient individuals, including those with chronic periodontitis, the natural feedback mechanism based on the induction of the vitamin D 24-hydroxylase enzyme guarantees that high concentrations of 1,25(OH)2D3 will not occur in the gingival epithelium. Because of this, hypervitaminosis D and other side effects are unlikely.
effects of high levels of supplementation are rare.44 However, to avoid both systemic feedback regulation and any potential systemic effects of supplementation, we propose that a topical administration of vitamin D could be useful. However, 1,25(OH)2D3 is highly labile and does not provide a strong foundation for a therapeutic agent. Thus, we would propose to use the inactive vitamin D3 (cholecalsicerol) form. In order for this inactive form of vitamin D3 to lead to both antibacterial peptide gene induction and pro-inflammatory cytokine inhibition, it must be converted to the active form in situ. We have previously demonstrated that this two-step activation occurs in airway epithelial cells,45 and here, we show that the same hydroxylase enzymes are expressed by gingival epithelial cells, allowing the use of cholecalciferol to be applied topically.

Vitamin D inhibits the expression of pro-inflammatory cytokines,46 most often demonstrated by the activity of 1,25(OH)2D3 in cultured cells that are stimulated with LPS or IL-1β to induce the expression of these cytokines.47,48 To demonstrate the activity of topical, inactive vitamin D in vivo in periodontally healthy mice, we identified a pro-inflammatory cytokine, IL-1α, whose basal expression was inhibited by vitamin D treatment in vitro. IL-1α is an important pro-inflammatory cytokine in the development of bone loss in periodontal disease,33 and thus, we examined the effect of vitamin D on its expression in vitro and in vivo. Our results demonstrate for the first time that topical administration of vitamin D in vivo can lead to a localized inhibition of the inflammatory response. This not only supports the hypothesis that normal levels of vitamin D maintain an anti-inflammatory state in the oral cavity, but that it may be possible to use topical administration of vitamin D to prevent or treat the inflammation associated with periodontal disease, in addition to enhancing the natural antimicrobial activity of the tissue.

ACKNOWLEDGEMENTS

This study was supported by grants from the US Public Health Service: NIH 1RO1DE22723 to GD; R21DE027017 and R01DE028258 (KLK), P30GM103331 (KLK); R01DE016593 (ÖY); and ST90DE021990-07 (DCB). EP was a recipient of the University of Florida University Scholars award. We thank Dr. Susmita Datta, Department of Biostatistics, College of Public Health and Health Professions, University of Florida, for assistance with the statistical analysis.

CONFLICT OF INTEREST

The authors have no competing financial interests.

ORCID

Gill Diamond https://orcid.org/0000-0002-3596-9773

REFERENCES

22. Lee J, Roberts JS, Atanasova KR, Chowdhury N, Han K, Yilmaz O. Human primary epithelial cells acquire an


SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.